ALEXANDRIA, Va., July 23 -- United States Patent no. 12,365,681, issued on July 22, was assigned to C4 Therapeutics Inc. (Watertown, Mass.).
"Dihydrobenzimidazolones for medical treatment" was invented by Roger Norcross (Basel, Switzerland), Annick Goergler (Basel, Switzerland), Fabian Dey (Basel, Switzerland) and Eric Andre Kusznir (Basel, Switzerland).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the...